Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB849 Administered in Subjects With Advanced Solid Tumors Alone and in Combination With Pembrolizumab

NCT05761223 is registered in ClinicalTrials.gov with 1ST Biotherapeutics, Inc. as lead sponsor.

NCT NCT05761223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05761223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB849 Administered in Subjects With Advanced Solid Tumors Alone and in Combination With Pembrolizumab
Lead sponsor
1ST Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 13, 2023
Completion date
October 31, 2026
Enrollment
151 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor